이 페이지의 번역은 실험적이며 개발 중입니다. 여러분의 환영합니다!

Hainan Huluwa Pharmaceutical Group 관리

관리 기준 확인 0/4

현재 CEO에 대한 정보가 충분하지 않습니다.

주요 정보

Jinping Liu

최고 경영자

n/a

총 보상

CEO 급여 비율	n/a
CEO 임기	no data
CEO 소유권	41.8%
경영진 평균 재임 기간	데이터 없음
이사회 평균 재임 기간	데이터 없음

최근 관리 업데이트

Recent updates

Risks To Shareholder Returns Are Elevated At These Prices For Hainan Huluwa Pharmaceutical Group Co., Ltd. (SHSE:605199)

Jun 07

Hainan Huluwa Pharmaceutical Group's (SHSE:605199) Shareholders Have More To Worry About Than Only Soft Earnings

May 03

CEO

Jinping Liu (54 yo)

no data

테뉴어

Ms. Liu Jinping serves as General Manager and Chairman of the Board at Hainan Huluwa Pharmaceutical Group Co., Ltd. and serves as its Director.

Hainan Huluwa Pharmaceutical Group 관리

관리 기준 확인 0/4

주요 정보

최근 관리 업데이트

Hainan Huluwa Pharmaceutical Group Co., Ltd., Annual General Meeting, May 22, 2024

Hainan Huluwa Pharmaceutical Group Co., Ltd., Annual General Meeting, May 22, 2024

Recent updates

Hainan Huluwa Pharmaceutical Group Co., Ltd. to Report First Half, 2024 Results on Aug 29, 2024

Risks To Shareholder Returns Are Elevated At These Prices For Hainan Huluwa Pharmaceutical Group Co., Ltd. (SHSE:605199)

Hainan Huluwa Pharmaceutical Group's (SHSE:605199) Shareholders Have More To Worry About Than Only Soft Earnings

Hainan Huluwa Pharmaceutical Group Co., Ltd., Annual General Meeting, May 22, 2024

First quarter 2024 earnings released: EPS: CN¥0.07 (vs CN¥0.10 in 1Q 2023)

Hainan Huluwa Pharmaceutical Group Co., Ltd., Annual General Meeting, May 22, 2024

Hainan Huluwa Pharmaceutical Group Co., Ltd. to Report Q1, 2024 Results on Apr 27, 2024

Investor sentiment deteriorates as stock falls 18%

Hainan Huluwa Pharmaceutical Group Co., Ltd. to Report Fiscal Year 2023 Results on Apr 27, 2024

New minor risk - Share price stability

Third quarter 2023 earnings released: EPS: CN¥0.04 (vs CN¥0.036 in 3Q 2022)

Second quarter 2023 earnings released: EPS: CN¥0.05 (vs CN¥0.074 in 2Q 2022)

Hainan Huluwa Pharmaceutical Group Co., Ltd. to Report First Half, 2023 Results on Aug 29, 2023

First quarter 2023 earnings released: EPS: CN¥0.10 (vs CN¥0.07 in 1Q 2022)

Hainan Huluwa Pharmaceutical Group Co., Ltd.(XSSC:605199) dropped from S&P Global BMI Index

Third quarter 2022 earnings released: EPS: CN¥0.036 (vs CN¥0.06 in 3Q 2021)

Second quarter 2022 earnings released: EPS: CN¥0.07 (vs CN¥0.07 in 2Q 2021)

First quarter 2022 earnings released: EPS: CN¥0.07 (vs CN¥0.06 in 1Q 2021)

Investor sentiment deteriorated over the past week

Investor sentiment improved over the past week

Investor sentiment deteriorated over the past week

Investor sentiment improved over the past week

Third quarter 2021 earnings released: EPS CN¥0.06 (vs CN¥0.087 in 3Q 2020)

Second quarter 2021 earnings released: EPS CN¥0.07 (vs CN¥0.071 in 2Q 2020)

Investor sentiment deteriorated over the past week

Full year 2020 earnings released: EPS CN¥0.32 (vs CN¥0.33 in FY 2019)

Investor sentiment improved over the past week

New 90-day low: CN¥18.25

Hainan Huluwa Pharmaceutical Group Co., Ltd. announced that it expects to receive CNY 1 billion in funding

Investor sentiment deteriorated over the past week

New 90-day low: CN¥19.33

New 90-day low: CN¥21.91

New 90-day low: CN¥24.02

Market bids up stock over the past week

New 90-day low: CN¥25.14

New 90-day low: CN¥25.81

Third quarter earnings released

111, Inc. Teams Up with Huluwa Pharmaceutical to Explore the New Domain of Internet and pharmaceutical

First half earnings released

Hainan Huluwa Pharmaceutical Group Co., Ltd. to Report First Half, 2020 Results on Aug 28, 2020

CEO

테뉴어